Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Ginsenoside-containing medicine composition

A technology of ginsenoside and composition, applied in the field of medicine, can solve the problem of less reports on the pharmacological activity of Panax notoginseng saponins, and achieve the effect of enhancing the immune response function of the body

Inactive Publication Date: 2015-08-05
YUNNAN PUYOU BIOTECH CO LTD
View PDF5 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are few reports on the pharmacological activity of notoginseng saponin ft1

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ginsenoside-containing medicine composition
  • Ginsenoside-containing medicine composition
  • Ginsenoside-containing medicine composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] The preparation of embodiment 1 injection

[0016] Weigh 50g of arginine and water of equal quality, stir evenly, add 100g of ginsenoside Rg3, 62g of ginsenoside Rh2, and 88g of notoginsenoside ft1, heat to 50°C, stir to dissolve, and adjust the pH value with an aqueous solution containing 9% hydrochloric acid to 4.6, add water to the full amount, and stir evenly; then add activated carbon with a liquid volume of 0.1% (g / ml), stir for 25 minutes, and decarbonize by coarse filtration; pass through a 0.22 μm filter membrane to obtain a refined filtrate; potting, each The bottled volume is 2mL; autoclave at 118°C for 18 minutes, inspect, pack, and store.

Embodiment 2

[0017] The preparation of embodiment 2 tablet

[0018] 1) Mix 16 g of ginsenoside Rg3, 10 g of ginsenoside Rh2 and 14 g of notoginsenoside ft1 and stir evenly to obtain a powdery solid;

[0019] 2) Mix the powder obtained in step (1) with 60 g of lactose, 3 g of sodium carboxymethyl starch and 4.5 g of micropowdered silica gel, add 60 g of arginine to make a suitable soft material, and granulate with a 20-mesh sieve;

[0020] 3) Mix 5.5 g of sodium carboxymethyl starch and 2.1 g of micropowder silica gel with the dry granules obtained in step (2), and compress into tablets to obtain tablets.

Embodiment 3

[0021] Embodiment 3 capsule preparation

[0022] Weigh 16g of ginsenoside Rg3, 10g of ginsenoside Rh2, and 14g of notoginsenoside ft1, add 274g of starch, mix well, sieve, use ethanol aqueous solution as a binder to make a suitable soft material, granulate with 18 mesh sieve, 60°C Dry in an oven for 5 hours, sieve through a 16-mesh sieve, add 2 g of magnesium stearate, and mix well to obtain capsules.

[0023] The application of the composition of the present invention in antitumor will be described below in conjunction with specific experiments.

[0024] Experimental animals: Kunming mice were purchased from the Experimental Animal Center of Kunming Medical College.

[0025] Cells: B16 melanoma cells (B16melanoma cell) and human hepatoma cell (HepG2) cells were purchased from American Type Cell Bank (ATCC, Hanassas, VA, USA).

[0026] Medium: DMEM (FBS; HyClone, Logan, UT, USA) for cell culture, supplemented with 10% fetal bovine serum (FBS; HyClone, Logan, UT, USA), 0.03% ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Half inhibitory concentrationaaaaaaaaaa
Login to View More

Abstract

The invention discloses a ginsenoside-containing medicine composition. The ginsenoside-containing medicine composition comprises the following active ingredients by weight percent: 20-70 percent of ginsenoside Rg, 10-40 percent of ginsenoside Rh2 and 20-50 percent of notoginsenoside ft1. The invention also provides application of the composition to drugs for preventing and treating cancers, auxiliary anti-cancer drugs and medicines or health products used for strengthening the organic immunity. The ginsenoside-containing medicine composition can effectively inhibit tumor cells and stimulate lymphocyte proliferation, has excellent pharmacological effects, and has better security on the basis of saving resources and taking better drug effects.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a pharmaceutical composition containing ginsenoside. Background technique [0002] Cancer is a common and frequently-occurring disease, which poses a serious threat to people's life and health, and has a huge impact on national economic construction. The incidence of cancer in the world and in my country is increasing year by year. In my country, about 1.6 million people are newly diagnosed with cancer and about 1.3 million people die from cancer every year. At the current level of cancer death in our country, 2 people die of cancer every minute in the country, and more than 2,800 people will be killed by cancer every day, which is equivalent to the destruction of a city with a population of one million in one year. In the United States, cancer treatment costs $83 billion annually, accounting for 14% of national medical expenses. Almost everyone feels threatened b...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/704A23L1/29A61P35/00A61P37/04A23L33/00
Inventor 沈勇罗杰邓毅吴亚敏卢文静苏瑞
Owner YUNNAN PUYOU BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com